The trajectory of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key territories has introduced considerable risk . Investors are now facing the effect of generic competitio